Business Wire

Nexo Unveils Zero-interest Credit with 0% APR and No Fees

8.1.2026 15:00:00 CET | Business Wire | Press Release

Share

Nexo, the premier digital assets wealth platform, today announced the launch of Zero-interest Credit (ZiC), now joining the Nexo Credit Line as a flagship borrowing solution. ZiC enables Bitcoin and Ethereum holders to access liquidity at 0% interest through a fixed-duration term, free from the risk of premature forced liquidation.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260108785934/en/

Zero-interest Credit by Nexo

Previously available through Nexo’s Private and OTC services, structured zero-interest borrowing has been used by Nexo’s private channels and is now broadly available through Zero-interest Credit. In 2025, it has enabled access to more than $140 million in liquidity.

A broad solution for investors, traders, and businesses

Zero-interest Credit is designed for clients who want liquidity without sacrificing their long-term positioning. It supports BTC and ETH holders who prefer not to sell, affluent investors managing the timing of taxable events or funding major purchases, active traders pursuing market opportunities with defined risk, and businesses using digital assets to finance operations or strategic plans.

Built for peace of mind

ZiC brings a level of predictability rarely seen in crypto-backed credit. Instead of monitoring LTV ratios or worrying about market-driven liquidations, clients borrow at 0% interest with a structure that stays intact. Every ZiC position comes with a predefined repayment path that is fully visible from day one. Clients select the term and amount, and ZiC’s built-in Minimum Repayment Price ensures the loan cannot be liquidated mid-term, while the Maximum Repayment Price enables clients to lock in gains up to that level. At maturity, repayment is straightforward, with the option to settle in stablecoins or with collateral based on where the market stands relative to their predefined range. And for those who want continued exposure, ZiC Renewal makes it possible to extend the arrangement with refreshed terms, without unwinding or re-establishing the loan.

“Borrowers today want liquidity that is cost-efficient, clear, and free from the uncertainty of liquidation risk,” said Elitsa Taskova, Chief Product Officer at Nexo. “Zero-interest Credit gives them exactly that—a fully predefined borrowing structure they can rely on from start to finish.”

Setting a new standard for responsible crypto lending

As borrowing demand grows and major digital assets consolidate their role as the industry’s strongest collateral base, the market is shifting from interest-driven credit to structured models that prioritize predictability and client control. Crypto-collateralised lending reached $73.59 billion in Q3 2025, up 38.5% quarter-over-quarter and surpassing the previous cycle peak1 — reflecting stronger collateral quality and deeper institutional participation.

As a pioneer of crypto-backed credit — and today the world’s #2 crypto lender2 — Nexo continues to shape the industry. Zero-Interest Credit positions Nexo at the forefront of responsible credit innovation — delivering a solution shaped for the borrowing landscape as it stands today.

About Nexo

Nexo is a premier digital assets wealth platform designed to empower clients to grow, manage, and preserve their crypto holdings. Our mission is to lead the next generation of wealth creation by focusing on customer success and delivering tailored solutions that build enduring value, supported by 24/7 client care.

Since 2018, Nexo has provided unmatched opportunities to forward-thinking clients in over 150+ jurisdictions. With over $11 billion in AUM and $371 billion processed, we bring lasting value to millions worldwide. Our all-in-one platform combines advanced technology with a client-first approach, offering high-yield flexible and fixed-term savings, crypto-backed loans, sophisticated trading tools, and liquidity solutions, including the first crypto debit/credit card. Built on deep industry expertise, a sustainable business model, robust infrastructure, stringent security, and global licensing, Nexo champions innovation and long-lasting prosperity.

Official website: nexo.com

1Coinspeaker - Crypto Lending Hits $73.6B Record as DeFi Captures Two-Thirds of Market

2Galaxy Research - The State of Crypto Leverage – Q3 2025

View source version on businesswire.com: https://www.businesswire.com/news/home/20260108785934/en/

Contacts

communications@nexo.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye